{"gene":"RRM2B","run_date":"2026-06-10T07:46:28","timeline":{"discoveries":[{"year":2001,"finding":"Recombinant human and mouse p53R2 proteins contain an iron-tyrosyl free radical center and form an active ribonucleotide reductase (RNR) complex with the R1 protein, demonstrating that R1 is the functional partner of p53R2 and that the R1-p53R2 complex can supply resting cells with deoxyribonucleotides for DNA repair.","method":"In vitro reconstitution of RNR activity with purified recombinant proteins; EPR spectroscopy to detect iron-tyrosyl radical; UV irradiation of serum-starved G0/G1 mouse fibroblasts with R1 promoter-luciferase reporter","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro reconstitution of enzymatic activity with purified proteins, EPR spectroscopy for radical center, and cell-based functional validation in a single rigorous study","pmids":["11517226"],"is_preprint":false},{"year":2001,"finding":"p53R2 protein accumulates in the nucleus after DNA damage (gamma-irradiation), whereas R2 remains cytoplasmic; nuclear accumulation of p53R2 correlates with elevated RNR-dependent DNA synthesis activity after DNA damage. A point mutation in p53R2 in the HCT116 cancer cell line abolishes RNR activity, leading to enhanced p53AIP1-mediated apoptosis.","method":"Western blot of nuclear/cytoplasmic fractions; RNR activity assay; site-directed mutagenesis; gamma-irradiation of cells","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — subcellular fractionation with functional RNR activity assay and mutagenesis, single lab study","pmids":["11719458"],"is_preprint":false},{"year":2003,"finding":"Rrm2b-null mice show severe dNTP pool attenuation in mouse embryonic fibroblasts under oxidative stress, increased spontaneous mutation frequency in kidneys, p53 activation, and early death from renal failure, establishing that p53R2 is required in vivo for dNTP supply for DNA repair in resting cells.","method":"Rrm2b knockout mouse generation; dNTP pool measurement; TUNEL staining; spontaneous mutation assay; p53 target gene transcription analysis","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with multiple orthogonal phenotypic and biochemical readouts, published in high-impact journal","pmids":["12858174"],"is_preprint":false},{"year":2003,"finding":"Wild-type p53 directly interacts with both p53R2 and hRRM2 subunits (but not hRRM1) in co-immunoprecipitation experiments. After UV irradiation, p53R2 and hRRM2 dissociate from p53 and translocate with hRRM1 to the nucleus, where increased RNR activity is detected. This nuclear translocation and p53 dissociation are deficient in cells expressing mutant p53.","method":"Co-immunoprecipitation; confocal microscopy for colocalization; in vivo RNR activity assay; UV irradiation","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and confocal microscopy with functional RNR activity assay, single lab","pmids":["12615712"],"is_preprint":false},{"year":2004,"finding":"Purified recombinant p53R2 forms active RNR with hRRM1 via a C-terminal heptapeptide binding site shared with hRRM2, but with 4.76-fold lower binding affinity for hRRM1 than hRRM2. p53R2-containing RNR has ~20–50% lower kinetic activity than hRRM2-containing RNR. p53R2 is 158-fold more susceptible to the iron chelator deferoxamine mesylate than hRRM2, whereas it is 2.5-fold less sensitive to hydroxyurea; the iron center and tyrosyl radical are required for RNR activity.","method":"In vitro [3H]CDP reduction assay; synthetic heptapeptide competition assay; atomic absorption spectrometry for iron content; EPR for tyrosyl radical; deferoxamine and hydroxyurea inhibition studies","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic reconstitution with multiple inhibitor and binding assays, rigorous biochemical characterization, single lab","pmids":["14729598"],"is_preprint":false},{"year":2007,"finding":"Loss-of-function mutations in RRM2B (nonsense, missense, splice-site, in-frame deletions) cause severe mitochondrial DNA (mtDNA) depletion in humans, and Rrm2b-/- mice show severe mtDNA depletion in multiple tissues, demonstrating that p53R2 is required for dNTP supply for mtDNA synthesis.","method":"RRM2B sequencing in human patients; Southern blot/quantitative PCR for mtDNA copy number in human tissues and Rrm2b-/- mouse tissues","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — human genetics plus mouse knockout model, replicated across multiple families and tissues, independently replicated by subsequent studies","pmids":["17486094"],"is_preprint":false},{"year":2007,"finding":"In quiescent human fibroblasts lacking R2, the R1-p53R2 complex supports a complete de novo deoxyribonucleotide synthesis pathway (including thymidylate synthesis), with the primary function of providing dNTPs for mitochondrial DNA replication rather than nuclear DNA synthesis.","method":"Isotope incorporation with [5-3H]cytidine, [6-3H]deoxycytidine, [CH3-3H]thymidine in confluent quiescent human fibroblasts; measurement of dNTP pools and nucleoside export","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct isotope flux measurements in quiescent cells with multiple tracers, rigorous biochemical assay, single lab","pmids":["17416930"],"is_preprint":false},{"year":2007,"finding":"p53R2 physically interacts with p21 in vivo; the N-terminal region (aa 1–113) of p53R2 interacts with the N-terminal region (aa 1–93) of p21. In response to UV, p53R2 dissociates from p21, facilitates nuclear accumulation of p21, and RNR activity increases, suggesting p53R2 cooperates with p21 during G1 DNA repair arrest.","method":"Co-immunoprecipitation; mammalian two-hybrid assay; confocal microscopy; UV irradiation; RNR activity assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and mammalian two-hybrid defining interaction domain, with functional RNR assay, single lab","pmids":["17210678"],"is_preprint":false},{"year":2008,"finding":"ATM phosphorylates p53R2 at Ser72 within 30 minutes of genotoxic stress, and p53R2 and its partner RRM1 are associated with ATM in vivo. Ser72 phosphorylation stabilizes p53R2 by preventing MDM2-mediated ubiquitination and degradation; the S72A mutant shows hyperubiquitination, reduced stability, and impaired DNA damage resistance.","method":"In vivo co-immunoprecipitation of p53R2/RRM1 with ATM; site-directed mutagenesis (S72A); ubiquitination assay; Western blot for protein stability; ATM kinase inhibitor treatment","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — mutagenesis with ubiquitination assay and Co-IP defining writer (ATM) and reader/eraser (MDM2) in a single rigorous study","pmids":["19015526"],"is_preprint":false},{"year":2009,"finding":"A heterozygous truncating mutation in RRM2B (p.R327X) removes 25 highly conserved C-terminal amino acids essential for interaction with the R1 subunit of ribonucleotide reductase, causing autosomal-dominant progressive external ophthalmoplegia with multiple mtDNA deletions, consistent with a dominant-negative or gain-of-function mechanism.","method":"Genetic linkage mapping; RRM2B sequencing; nonsense-mediated decay analysis; protein truncation assessment; family segregation analysis","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and molecular characterization, functional inference from C-terminal domain loss, two independent families, single lab","pmids":["19664747"],"is_preprint":false},{"year":2009,"finding":"Gemcitabine 5'-diphosphate (F2CDP) is a substoichiometric inactivator of the human RNR alpha/p53R2 (beta') complex; inactivation results in covalent attachment of ~0.5 equiv sugar to alpha subunit and release of cytosine, with cross-linking observed by SDS-PAGE. Active site mutants (C444S/A, C218S/A, E431Q/D) do not bind the sugar label, establishing that inactivation requires the catalytic active site of the alpha (R1) subunit.","method":"In vitro [1'-3H]-F2CDP and [5-3H]-F2CDP radiolabel incorporation; SDS-PAGE; size exclusion chromatography; active site mutagenesis of alpha subunit; Sephadex G-50 reisolation","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with radiolabeled substrate and active-site mutagenesis defining the mechanism of inactivation, single rigorous study","pmids":["19899807"],"is_preprint":false},{"year":2009,"finding":"The 2.6 Å X-ray crystal structure of human p53R2 reveals monomers with mono- and binuclear iron occupancy; pronounced structural differences at three regions from hRRM2 explain differences in iron assimilation, mobility/accessibility of the radical iron center, and radical transfer pathways between the two enzymes.","method":"X-ray crystallography at 2.6 Å resolution","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with functional interpretation, definitive structural determination","pmids":["19728742"],"is_preprint":false},{"year":2009,"finding":"p53R2 interacts physically with MEK2 (ERK kinase 2) in co-immunoprecipitation and immunofluorescence assays; the p53R2 segment aa 161–206 is critical for this interaction. p53R2 negatively modulates serum-induced MEK-ERK signaling: knockdown of p53R2 augments MEK1/2 and ERK1/2 phosphorylation, while overexpression attenuates it. MEK2 is required for p53R2 knockdown-enhanced invasion and anchorage-independent growth.","method":"Co-immunoprecipitation; immunofluorescence; siRNA knockdown; overexpression; phosphorylation assay by Western blot; Matrigel invasion assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP defining interaction domain plus functional epistasis by siRNA/overexpression, single lab","pmids":["19398949"],"is_preprint":false},{"year":2011,"finding":"In quiescent (but not cycling) patient fibroblasts carrying a lethal missense mutation in p53R2, mtDNA synthesis is defective after ethidium bromide depletion and recovery, and UV-induced DNA repair is impaired (delayed dsDNA recovery, prolonged γH2AX phosphorylation). Supplementation with deoxynucleosides restored dNTP pools, mtDNA synthesis, and DNA repair, confirming that p53R2-dependent ribonucleotide reduction is specifically required for mtDNA maintenance and DNA repair in quiescent cells.","method":"Ethidium bromide depletion/recovery assay for mtDNA; fluorometric analysis of DNA unwinding (FADU) for repair; γH2AX Western blot; dNTP pool measurement; deoxynucleoside supplementation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal functional assays in patient cells, rescue by deoxynucleoside supplementation provides mechanistic proof, single lab with rigorous controls","pmids":["22847445"],"is_preprint":false},{"year":2011,"finding":"In Kearns-Sayre syndrome caused by two novel RRM2B missense mutations, Blue-native PAGE demonstrates reduced heterotetrameric R1/p53R2 RNR levels despite normal steady-state p53R2 on Western blot, establishing that defective R1/p53R2 RNR assembly is a disease mechanism.","method":"Western blot; Blue-native polyacrylamide gel electrophoresis (BN-PAGE); RRM2B DNA sequencing","journal":"Journal of medical genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — BN-PAGE directly demonstrating impaired protein complex assembly in patient cells, single lab","pmids":["21378381"],"is_preprint":false},{"year":2006,"finding":"Purified recombinant p53R2 has catalase activity (breaks down H2O2) and reduces intracellular ROS while protecting mitochondrial membrane potential against oxidative stress, in contrast to hRRM2 which increases ROS. Site-directed mutagenesis identified Y331, Y285, Y49, and Y241 as critical residues for antioxidant activity; these mutations also negatively correlated with RNR enzymatic activity.","method":"Cell-free ROS assay with carboxy-H2DCFDA; catalase activity assay with purified protein; mitochondrial membrane potential assay; site-directed mutagenesis; overexpression in cells","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro catalase assay with purified protein plus mutagenesis defining critical residues, complemented by cell-based assays, single rigorous study","pmids":["16488986"],"is_preprint":false},{"year":2012,"finding":"Rrm2b gene loss causes severe numerical and structural chromosomal abnormalities leading to ATM activation, which induces IKKγ/NEMO phosphorylation at pSer85, activating IKK and NF-κB, resulting in sustained IL-6 expression and constitutive STAT3 activation. Genetic ablation of IL-6 suppressed STAT3 and delayed disease onset in Rrm2b-/- mice, establishing this pathway as causal for inflammation-associated tumorigenesis.","method":"Rrm2b knockout mouse; cytogenetic analysis; ATM and IKK phosphorylation assays; NF-κB and STAT3 activation; IL-6 ELISA; IL-6 genetic knockout cross; mouse lifespan analysis","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in vivo (IL-6 KO rescue), biochemical pathway mapping, multiple orthogonal methods in a single study","pmids":["23643536"],"is_preprint":false},{"year":2012,"finding":"p53R2 overexpression reduces intracellular ROS, maintains mtDNA content, and supports cytochrome c oxidase activity and ATP synthesis; siRNA knockdown of p53R2 reduces mtDNA content, impairs mitochondrial function (ATP synthesis, COX activity, membrane potential), and increases ROS, establishing a role for p53R2 in mitochondrial homeostasis beyond dNTP synthesis.","method":"siRNA knockdown; overexpression; mtDNA quantification by PCR; ATP synthesis assay; cytochrome c oxidase activity assay; mitochondrial membrane potential assay; ROS measurement","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays in siRNA KD and OE cells, single lab, no in vivo validation","pmids":["21640705"],"is_preprint":false},{"year":2012,"finding":"RRM2B is highly induced in a p53-dependent manner during senescence; silencing RRM2B increases ROS, induces mitochondrial membrane depolarization, and causes premature senescence in a p38MAPK- and p53-dependent manner. Senescence is accelerated in Rrm2b-deficient MEFs.","method":"RRM2B siRNA knockdown in IMR90 fibroblasts; senescence assays; ROS measurement; mitochondrial membrane potential assay; p38MAPK inhibitor treatment; Rrm2b-/- MEFs","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown plus genetic KO MEFs with multiple pathway inhibitors, single lab","pmids":["23139867"],"is_preprint":false},{"year":2012,"finding":"MEK2 regulates RNR activity through a direct interaction with p53R2; the MEK2 segment aa 65–171 is critical for p53R2 binding. Inhibition of MEK2 (by siRNA or pharmacological inhibitor) dramatically decreases serum-stimulated RNR activity, and p53R2 siRNA (but not R2 siRNA) inhibits this activity, indicating specific MEK2-p53R2 regulation. Ionizing radiation activates MEK1/2 and increases RNR activity, which is attenuated by MEK2 or p53R2 siRNA.","method":"Co-immunoprecipitation; MEK2 siRNA; MEK inhibitor; RNR activity assay; ionizing radiation","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain mapping and functional RNR assay, confirmed with siRNA and pharmacological inhibitor, single lab","pmids":["22895183"],"is_preprint":false},{"year":2016,"finding":"PYCR1 and PYCR2 were identified by mass spectrometry as components of RRM2B complexes. Silencing of both PYCR1 and PYCR2 abolished the antioxidant activity of RRM2B overexpression, demonstrating a functional collaboration between RRM2B, PYCR1, and PYCR2 in protecting cells from oxidative stress.","method":"Large-scale Flag-tagged RRM2B complex purification; mass spectrometry; shRNA silencing of PYCR1/PYCR2; oxidative stress assays; mitochondrial network analysis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS-based interactome followed by functional shRNA validation, single lab","pmids":["26733354"],"is_preprint":false},{"year":2014,"finding":"FOXO3 directly binds to the RRM2B promoter and transcriptionally activates RRM2B expression at RNA and protein levels independently of p53, establishing FOXO3 as a novel p53-independent regulator of RRM2B.","method":"Chromatin immunoprecipitation (ChIP); promoter luciferase assay; FOXO3 overexpression; Western blot and RT-PCR; cancer cell proliferation assay","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and promoter assay establishing direct transcriptional regulation, single lab","pmids":["24947616"],"is_preprint":false},{"year":2019,"finding":"The glutathione-glutaredoxin (GSH-Grx) system is 4–6 times more catalytically efficient than the thioredoxin-1 (Trx1) system as electron donor for mammalian R1-p53R2 RNR, with Vmax for Grx strongly dependent on GSH concentration. GSH reductase is essential for this reaction. This identifies the C-terminal swinging-arm dithiol/disulfide of R1 as having a crucial catalytic role in reduction for p53R2-containing RNR.","method":"In vitro RNR activity assay with mouse R1-p53R2; comparison of Grx vs Trx1 electron donor systems; Vmax/Km kinetic measurements; GSH reductase dependency assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with kinetic characterization of electron donor systems, rigorous biochemical study, single lab","pmids":["31266802"],"is_preprint":false},{"year":2016,"finding":"p53R2 interacts with mitochondrial thioredoxin reductase 2 (TrxR2) and stimulates TrxR enzymatic activity in vitro. TrxR2 activity is significantly lower in p53R2 knockdown cells and increased upon p53R2 overexpression in a p53-independent manner; p53R2 knockdown also suppresses UV-induced TrxR activity.","method":"Co-immunoprecipitation; in vitro TrxR activity assay; siRNA knockdown; overexpression; UV irradiation","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with in vitro activity assay and cell-based knockdown/overexpression, single lab","pmids":["27866984"],"is_preprint":false},{"year":2015,"finding":"During apoptosis, p53R2 is cleaved in a caspase-dependent manner (by caspase-3 and caspase-8) between Asp342 and Asn343, releasing a C-terminal 9-residue peptide containing the conserved heptapeptide essential for R1 binding, rendering the cleaved p53R2 inactive. R1 is not degraded during apoptosis.","method":"Cell treatment with Bcr-Abl inhibitors and TNF-α/cycloheximide; Western blot for cleavage products; in vitro cleavage by purified caspase-3 and -8; caspase-specific siRNA knockdown; cleavage site mapping","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified caspases defining the cleavage site, complemented by cell-based siRNA epistasis, single rigorous study","pmids":["25878246"],"is_preprint":false},{"year":2006,"finding":"Circular dichroism and magnetic circular dichroism spectroscopy of p53R2 revealed a biferrous active site with one five-coordinate and one four-coordinate iron weakly antiferromagnetically coupled through mu-1,3-carboxylate bridges; both human and mouse p53R2 have high Fe(II) affinity, distinct from mouse R2, potentially reflecting differences in regulation of enzymatic activity.","method":"Circular dichroism (CD); magnetic circular dichroism (MCD); variable-temperature variable-field MCD; EPR spectroscopy; Fe(II) titration for metal binding affinity","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal spectroscopic methods (CD, MCD, VTVH-MCD, EPR) in a single rigorous study; definitive active site characterization","pmids":["17115699"],"is_preprint":false},{"year":2023,"finding":"CK2 (casein kinase II) phosphorylates p53R2 at Ser20, activating RNR for dNTP production. Loss of p53R2 impairs homologous recombination (HR) repair by reducing CtIP levels through dNTP shortage-induced ubiquitination of CtIP. Pharmacologic inhibition of CK2-mediated p53R2 Ser20 phosphorylation compromises HR repair in BRCA1/2-WT cancer cells and sensitizes them to PARP inhibitors.","method":"CK2 kinase assay; phospho-specific antibody; siRNA depletion of p53R2; ubiquitination assay for CtIP; HR repair reporter assay; PARP inhibitor sensitivity assay in vitro and in vivo","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinase identification with functional epistasis showing HR pathway placement, in vitro and in vivo validation, single lab","pmids":["37620447"],"is_preprint":false},{"year":2021,"finding":"p53R2 (and R2) subunits of mammalian RNR can be S-glutathionylated in vitro, and the Grx1 system efficiently deglutathionylates the S-glutathionylated p53R2, suggesting S-glutathionylation as a redox regulatory mechanism for p53R2 activity.","method":"In vitro S-glutathionylation assay; Grx1-mediated deglutathionylation assay; Western blot with anti-glutathione antibody","journal":"Molecular biology reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — in vitro modification only, no functional activity assay after glutathionylation, single method, single lab","pmids":["34599703"],"is_preprint":false},{"year":2025,"finding":"In Rrm2b knockout mouse tissues, RRM2B deficiency selectively depletes dATP and dGTP pools while dCTP and dTTP remain stable or increase. Mechanistically, this is attributed to preferred degradation of dATP and dGTP by the dNTPase SAMHD1 combined with lower RNR production rate of dATP.","method":"Rrm2b knockout mouse model; dNTP pool measurement in non-dividing tissues; SAMHD1 substrate preference analysis; comparison with hydroxyurea-treated controls","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout with quantitative dNTP pool measurement and mechanistic attribution to SAMHD1, single lab but rigorous in vivo model","pmids":["40244665"],"is_preprint":false},{"year":2005,"finding":"In vitro reconstitution using eukaryotically expressed and purified hRRM1, hRRM2, and p53R2 confirmed that both hRRM2 and p53R2 interact with hRRM1 to form functional RNR holoenzyme; hRRM2 and p53R2 share the same binding site on hRRM1 (competitive C-terminal heptapeptide), but hRRM1 has higher affinity for hRRM2 than p53R2. ATP and dATP allosteric regulation of hRRM1 is independent of which small subunit is present.","method":"Eukaryotic expression and purification of RNR subunits; [3H]CDP reduction assay; synthetic C-terminal heptapeptide competition assay; allosteric regulation assay with ATP/dATP","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with kinetic and competition assays, replicated from prior in vitro work using eukaryotic system, single lab","pmids":["16376858"],"is_preprint":false}],"current_model":"RRM2B (p53R2) encodes the small subunit of a ribonucleotide reductase (RNR) complex that pairs with the R1 catalytic subunit (RRM1) via a conserved C-terminal heptapeptide to form an active enzyme; the p53R2 monomer harbors an iron-tyrosyl radical center (structurally resolved at 2.6 Å) required for catalysis, is specifically induced by p53 in response to DNA damage and by FOXO3 independently of p53, is rapidly stabilized by ATM-mediated Ser72 phosphorylation (protecting it from MDM2-dependent ubiquitination) and activated by CK2-mediated Ser20 phosphorylation, is inactivated by caspase-3/8 cleavage at Asp342 during apoptosis, supplies dNTPs (preferentially dATP and dGTP) for nuclear DNA repair and mitochondrial DNA replication especially in quiescent/non-dividing cells, scavenges reactive oxygen species through a catalase-like activity requiring specific tyrosine residues, interacts with p21 and MEK2 to modulate cell cycle arrest and ERK signaling, collaborates with PYCR1/PYCR2 for antioxidant protection and with TrxR2 in mitochondria, and is reduced by the GSH-Grx electron donor system with higher efficiency than by thioredoxin; loss of RRM2B causes selective depletion of dATP and dGTP, mtDNA depletion syndrome, chromosomal instability leading to NF-κB/IL-6/STAT3 pathway activation, and early lethality in mice and humans."},"narrative":{"mechanistic_narrative":"RRM2B (p53R2) encodes the small subunit of a ribonucleotide reductase (RNR) that supplies deoxyribonucleotides for genome maintenance in resting and non-dividing cells, the function in which it is most critical [PMID:11517226, PMID:12858174, PMID:17416930]. It harbors an iron-tyrosyl free radical center and pairs with the catalytic R1 subunit (RRM1) through a C-terminal heptapeptide—the same binding site used by the cycling-cell subunit R2 but with lower R1 affinity—to form an active holoenzyme [PMID:11517226, PMID:14729598, PMID:16376858]. Crystallographic and spectroscopic studies define a biferrous active site whose iron assimilation and radical-transfer properties differ from R2, accounting for its distinct kinetic and inhibitor sensitivities [PMID:19728742, PMID:17115699]. In quiescent cells the R1–p53R2 complex drives a complete de novo dNTP synthesis pathway dedicated chiefly to mitochondrial DNA replication and DNA repair [PMID:17416930, PMID:22847445]; its loss selectively depletes dATP and dGTP, an asymmetry attributable to SAMHD1-mediated degradation and lower RNR output of these nucleotides [PMID:40244665]. Expression is induced both by p53 and, independently, by FOXO3 binding the RRM2B promoter [PMID:24947616], while the protein is acutely regulated post-translationally: ATM phosphorylates Ser72 to block MDM2-dependent ubiquitination and stabilize it after genotoxic stress [PMID:19015526], CK2 phosphorylates Ser20 to activate dNTP production supporting CtIP-dependent homologous recombination [PMID:37620447], and caspase-3/8 cleavage at Asp342 removes the R1-binding heptapeptide to inactivate the enzyme during apoptosis [PMID:25878246]. Beyond nucleotide supply, p53R2 has intrinsic catalase-like antioxidant activity dependent on specific tyrosines, lowers ROS, and preserves mitochondrial membrane potential and function, acting with PYCR1/PYCR2 and stimulating mitochondrial TrxR2 [PMID:16488986, PMID:21640705, PMID:26733354, PMID:27866984]. It is reduced more efficiently by the glutathione-glutaredoxin system than by thioredoxin [PMID:31266802]. Loss-of-function and dominant C-terminal RRM2B mutations cause human mitochondrial DNA depletion syndromes, progressive external ophthalmoplegia, and Kearns-Sayre syndrome through impaired R1/p53R2 RNR assembly and mtDNA maintenance [PMID:17486094, PMID:19664747, PMID:21378381, PMID:22847445], and in mice Rrm2b loss produces chromosomal instability that activates ATM–IKK–NF-κB–IL-6–STAT3 signaling driving inflammation-associated disease [PMID:23643536].","teleology":[{"year":2001,"claim":"Established that p53R2 is a genuine RNR small subunit, resolving whether the p53-inducible protein had catalytic function rather than merely regulatory activity.","evidence":"In vitro reconstitution of RNR activity with purified recombinant p53R2 and R1, EPR detection of an iron-tyrosyl radical, and reporter assays in serum-starved fibroblasts","pmids":["11517226"],"confidence":"High","gaps":["Did not define affinity differences from R2","In vivo requirement not yet shown"]},{"year":2001,"claim":"Connected p53R2 to the DNA damage response by showing damage-induced nuclear accumulation and its requirement for RNR activity opposing apoptosis.","evidence":"Nuclear/cytoplasmic fractionation, RNR activity assay, and site-directed mutagenesis in gamma-irradiated cancer cells","pmids":["11719458"],"confidence":"Medium","gaps":["Mechanism of nuclear import undefined","Single cell-line mutation analysis"]},{"year":2003,"claim":"Demonstrated in vivo that p53R2 is required for dNTP supply and genome stability in resting cells, linking its loss to mutation and organismal lethality.","evidence":"Rrm2b-null mice with dNTP pool, mutation frequency, TUNEL and p53 target readouts","pmids":["12858174"],"confidence":"High","gaps":["Mitochondrial versus nuclear contribution not separated at this stage"]},{"year":2003,"claim":"Placed p53R2 in a p53-dependent regulatory circuit by showing p53 sequesters it until DNA damage triggers dissociation and nuclear translocation with R1.","evidence":"Co-immunoprecipitation, confocal colocalization, and in vivo RNR assay after UV in WT versus mutant p53 cells","pmids":["12615712"],"confidence":"Medium","gaps":["Direct binding interface with p53 not mapped","Single lab, reciprocal but not structural"]},{"year":2004,"claim":"Quantified the biochemical distinction between p53R2 and R2, showing shared R1-binding heptapeptide but lower affinity, lower activity, and distinct iron-chelator/hydroxyurea sensitivities.","evidence":"In vitro CDP reduction, heptapeptide competition, atomic absorption, EPR, and inhibitor studies","pmids":["14729598"],"confidence":"High","gaps":["Structural basis of affinity difference not resolved here"]},{"year":2005,"claim":"Confirmed in a eukaryotic expression system that R2 and p53R2 compete for the same R1 site and that allosteric ATP/dATP regulation is subunit-independent.","evidence":"Reconstitution of purified eukaryotic subunits with CDP reduction, heptapeptide competition, and allosteric assays","pmids":["16376858"],"confidence":"High","gaps":["In-cell competition dynamics not addressed"]},{"year":2006,"claim":"Revealed an unexpected antioxidant function: p53R2 has catalase-like activity that lowers ROS and protects mitochondrial membrane potential, mapped to specific tyrosines.","evidence":"Cell-free ROS and catalase assays with purified protein, mitochondrial membrane potential assay, and tyrosine mutagenesis","pmids":["16488986"],"confidence":"High","gaps":["Relationship between catalase and RNR activities mechanistically entangled via shared tyrosines"]},{"year":2006,"claim":"Characterized the diiron active site spectroscopically, defining a biferrous center with high Fe(II) affinity distinct from R2.","evidence":"CD, MCD, VTVH-MCD, EPR, and Fe(II) titration","pmids":["17115699"],"confidence":"High","gaps":["Functional consequence of high Fe affinity for in vivo regulation inferred not tested"]},{"year":2007,"claim":"Identified mitochondrial DNA maintenance as a primary in vivo role, establishing RRM2B mutations as a cause of human mtDNA depletion.","evidence":"RRM2B sequencing in patients and mtDNA copy-number quantification in human tissues and Rrm2b-/- mice","pmids":["17486094"],"confidence":"High","gaps":["Cell-type specificity of mtDNA depletion not fully resolved"]},{"year":2007,"claim":"Showed flux through the R1-p53R2 complex constitutes a complete de novo dNTP pathway in quiescent cells serving mtDNA replication.","evidence":"Isotope tracer incorporation in confluent quiescent human fibroblasts with dNTP pool and export measurement","pmids":["17416930"],"confidence":"High","gaps":["Salvage pathway interplay not quantified"]},{"year":2007,"claim":"Linked p53R2 to cell cycle arrest machinery via a defined interaction with p21 modulating p21 nuclear accumulation during repair.","evidence":"Co-IP, mammalian two-hybrid domain mapping, and confocal microscopy with RNR assay after UV","pmids":["17210678"],"confidence":"Medium","gaps":["Functional significance for arrest not genetically tested","Single lab"]},{"year":2008,"claim":"Defined the ATM-MDM2 axis controlling p53R2 stability, explaining how genotoxic stress rapidly stabilizes the protein.","evidence":"ATM Co-IP, S72A mutagenesis, ubiquitination and protein stability assays with ATM inhibitor","pmids":["19015526"],"confidence":"High","gaps":["Structural basis of phosphorylation-protected MDM2 interface unknown"]},{"year":2009,"claim":"Mapped the molecular consequence of a dominant C-terminal truncation, linking loss of R1 binding to autosomal-dominant PEO with mtDNA deletions.","evidence":"Linkage mapping, RRM2B sequencing, NMD and truncation analysis, family segregation","pmids":["19664747"],"confidence":"Medium","gaps":["Dominant-negative versus gain-of-function not biochemically distinguished"]},{"year":2009,"claim":"Determined the human p53R2 crystal structure, explaining its distinct iron handling and radical transfer relative to R2.","evidence":"X-ray crystallography at 2.6 Å","pmids":["19728742"],"confidence":"High","gaps":["Holoenzyme R1-p53R2 complex structure not determined"]},{"year":2009,"claim":"Defined the mechanism by which gemcitabine diphosphate inactivates the alpha/p53R2 complex through covalent active-site modification.","evidence":"Radiolabeled F2CDP incorporation, SDS-PAGE crosslinking, and alpha-subunit active-site mutagenesis","pmids":["19899807"],"confidence":"High","gaps":["In-cell relevance to gemcitabine therapy not addressed"]},{"year":2009,"claim":"Uncovered a non-canonical role linking p53R2 to MEK-ERK signaling and tumor cell invasion through a direct MEK2 interaction.","evidence":"Co-IP with domain mapping, immunofluorescence, siRNA/overexpression with invasion and anchorage-independent growth assays","pmids":["19398949"],"confidence":"Medium","gaps":["Whether this is RNR-dependent unclear","Single lab"]},{"year":2011,"claim":"Showed that defective R1/p53R2 RNR holoenzyme assembly underlies disease, even when p53R2 protein levels appear normal.","evidence":"BN-PAGE of RNR complex with Western blot and sequencing in Kearns-Sayre patient cells","pmids":["21378381"],"confidence":"Medium","gaps":["Structural defect in assembly not resolved"]},{"year":2011,"claim":"Provided mechanistic proof in patient cells that p53R2-dependent ribonucleotide reduction is specifically needed for mtDNA maintenance and repair in quiescence, rescuable by deoxynucleosides.","evidence":"Ethidium bromide depletion/recovery, FADU repair assay, γH2AX, dNTP pools, and deoxynucleoside supplementation","pmids":["22847445"],"confidence":"High","gaps":["Therapeutic durability of deoxynucleoside rescue not assessed"]},{"year":2012,"claim":"Established a causal inflammatory pathway whereby Rrm2b loss-driven chromosomal instability activates ATM-IKK-NF-κB-IL-6-STAT3 signaling.","evidence":"Rrm2b knockout cytogenetics, phosphorylation assays, IL-6 ELISA, IL-6 genetic rescue, and lifespan analysis","pmids":["23643536"],"confidence":"High","gaps":["Direct sensing event linking instability to ATM not detailed"]},{"year":2012,"claim":"Demonstrated that p53R2 supports mitochondrial bioenergetics and homeostasis beyond dNTP supply.","evidence":"siRNA/overexpression with mtDNA quantification, ATP synthesis, COX activity, membrane potential and ROS assays","pmids":["21640705"],"confidence":"Medium","gaps":["No in vivo validation","Secondary versus direct effects unresolved"]},{"year":2012,"claim":"Linked p53R2 to senescence control, showing its silencing triggers premature senescence via ROS and p38MAPK/p53.","evidence":"siRNA in IMR90 fibroblasts and Rrm2b-/- MEFs with senescence, ROS, membrane potential assays and p38 inhibition","pmids":["23139867"],"confidence":"Medium","gaps":["Single lab","Causality of ROS versus dNTP depletion not separated"]},{"year":2012,"claim":"Showed MEK2 directly regulates RNR activity through p53R2, integrating mitogenic signaling with nucleotide production.","evidence":"Co-IP domain mapping, MEK2 siRNA/inhibitor, and RNR activity assays after serum or ionizing radiation","pmids":["22895183"],"confidence":"Medium","gaps":["Mechanism by which MEK2 binding alters RNR catalysis unknown"]},{"year":2014,"claim":"Identified FOXO3 as a p53-independent transcriptional activator of RRM2B, broadening its regulatory inputs.","evidence":"ChIP, promoter luciferase, FOXO3 overexpression with RT-PCR and Western blot","pmids":["24947616"],"confidence":"Medium","gaps":["Physiological conditions invoking FOXO3 regulation not defined"]},{"year":2015,"claim":"Defined how apoptosis inactivates p53R2 through caspase-3/8 cleavage at Asp342 removing the R1-binding heptapeptide.","evidence":"In vitro cleavage with purified caspases, cleavage-site mapping, and caspase siRNA in apoptotic cells","pmids":["25878246"],"confidence":"High","gaps":["Physiological impact of dNTP loss during apoptosis not quantified"]},{"year":2016,"claim":"Identified PYCR1/PYCR2 as functional partners required for p53R2-mediated antioxidant protection.","evidence":"Flag-RRM2B complex purification with mass spectrometry and PYCR1/2 shRNA with oxidative stress assays","pmids":["26733354"],"confidence":"Medium","gaps":["Biochemical mechanism of the collaboration unresolved"]},{"year":2016,"claim":"Showed p53R2 interacts with and stimulates mitochondrial TrxR2, connecting it to the mitochondrial antioxidant system.","evidence":"Co-IP, in vitro TrxR activity assay, siRNA/overexpression, and UV stimulation","pmids":["27866984"],"confidence":"Medium","gaps":["Structural basis of TrxR2 stimulation unknown","Single lab"]},{"year":2019,"claim":"Defined the preferred electron-donor system for R1-p53R2, showing GSH-glutaredoxin is more efficient than thioredoxin.","evidence":"In vitro RNR activity kinetics comparing Grx and Trx1 systems with GSH reductase dependency","pmids":["31266802"],"confidence":"High","gaps":["In-cell reductant usage not measured"]},{"year":2021,"claim":"Proposed S-glutathionylation as a redox regulatory modification of p53R2 reversed by Grx1.","evidence":"In vitro S-glutathionylation and Grx1 deglutathionylation with anti-glutathione Western blot","pmids":["34599703"],"confidence":"Low","gaps":["No functional activity assay after glutathionylation","In vitro only, single method"]},{"year":2023,"claim":"Defined CK2-mediated Ser20 phosphorylation as an activating switch coupling p53R2 dNTP supply to CtIP stability and homologous recombination, with therapeutic implications for PARP inhibitors.","evidence":"CK2 kinase assay, phospho-specific antibody, p53R2 siRNA, CtIP ubiquitination, HR reporter, and PARP inhibitor sensitivity in vitro and in vivo","pmids":["37620447"],"confidence":"Medium","gaps":["Direct structural effect of Ser20 phosphorylation on RNR undefined","Single lab"]},{"year":2025,"claim":"Explained why RRM2B loss selectively depletes dATP and dGTP, attributing the asymmetry to SAMHD1 degradation preference and lower RNR output.","evidence":"Rrm2b knockout mouse dNTP pool measurement in non-dividing tissues with SAMHD1 substrate analysis","pmids":["40244665"],"confidence":"Medium","gaps":["Direct in vivo demonstration of SAMHD1 epistasis not performed"]},{"year":null,"claim":"How the multiple post-translational and protein-interaction inputs (ATM/Ser72, CK2/Ser20, MEK2, p21, redox modifications) are integrated to tune p53R2 activity in specific physiological contexts, and the structure of the assembled R1-p53R2 holoenzyme, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No holoenzyme structure","Integration of competing regulatory signals not modeled","In-cell electron-donor and redox regulation not directly measured"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,4,6,29]},{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,4,25]},{"term_id":"GO:0016209","term_label":"antioxidant activity","supporting_discovery_ids":[15,17]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[23]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,3]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,6]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[5,17,23]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[0,2,13,26]},{"term_id":"R-HSA-69306","term_label":"DNA Replication","supporting_discovery_ids":[5,6,13]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[6,28]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[15,18]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,9,14,16]}],"complexes":["Ribonucleotide reductase (R1/p53R2 holoenzyme)"],"partners":["RRM1","TP53","CDKN1A","MAP2K2","ATM","PYCR1","PYCR2","TXNRD2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q7LG56","full_name":"Ribonucleoside-diphosphate reductase subunit M2 B","aliases":["TP53-inducible ribonucleotide reductase M2 B","p53-inducible ribonucleotide reductase small subunit 2-like protein","p53R2"],"length_aa":351,"mass_kda":40.7,"function":"Plays a pivotal role in cell survival by repairing damaged DNA in a p53/TP53-dependent manner. Supplies deoxyribonucleotides for DNA repair in cells arrested at G1 or G2. Contains an iron-tyrosyl free radical center required for catalysis. Forms an active ribonucleotide reductase (RNR) complex with RRM1 which is expressed both in resting and proliferating cells in response to DNA damage","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q7LG56/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RRM2B","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/RRM2B","total_profiled":1310},"omim":[{"mim_id":"613077","title":"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 5; PEOA5","url":"https://www.omim.org/entry/613077"},{"mim_id":"612075","title":"MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITH RENAL TUBULOPATHY); MTDPS8A","url":"https://www.omim.org/entry/612075"},{"mim_id":"606868","title":"HOMEODOMAIN-INTERACTING PROTEIN KINASE 2; HIPK2","url":"https://www.omim.org/entry/606868"},{"mim_id":"604712","title":"RIBONUCLEOTIDE REDUCTASE REGULATORY TP53 INDUCIBLE SUBUNIT M2B; RRM2B","url":"https://www.omim.org/entry/604712"},{"mim_id":"603041","title":"MITOCHONDRIAL DNA DEPLETION SYNDROME 1 (MNGIE TYPE); MTDPS1","url":"https://www.omim.org/entry/603041"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/RRM2B"},"hgnc":{"alias_symbol":["p53R2"],"prev_symbol":[]},"alphafold":{"accession":"Q7LG56","domains":[{"cath_id":"1.10.620.20","chopping":"81-316","consensus_level":"medium","plddt":94.9187,"start":81,"end":316}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q7LG56","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q7LG56-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q7LG56-F1-predicted_aligned_error_v6.png","plddt_mean":85.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RRM2B","jax_strain_url":"https://www.jax.org/strain/search?query=RRM2B"},"sequence":{"accession":"Q7LG56","fasta_url":"https://rest.uniprot.org/uniprotkb/Q7LG56.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q7LG56/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q7LG56"}},"corpus_meta":[{"pmid":"17486094","id":"PMC_17486094","title":"Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion.","date":"2007","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17486094","citation_count":435,"is_preprint":false},{"pmid":"11517226","id":"PMC_11517226","title":"Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11517226","citation_count":169,"is_preprint":false},{"pmid":"12858174","id":"PMC_12858174","title":"Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12858174","citation_count":120,"is_preprint":false},{"pmid":"11719458","id":"PMC_11719458","title":"p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11719458","citation_count":116,"is_preprint":false},{"pmid":"12615712","id":"PMC_12615712","title":"Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12615712","citation_count":108,"is_preprint":false},{"pmid":"22847445","id":"PMC_22847445","title":"Mammalian ribonucleotide reductase subunit p53R2 is required for mitochondrial DNA replication and DNA repair in quiescent cells.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22847445","citation_count":101,"is_preprint":false},{"pmid":"19664747","id":"PMC_19664747","title":"A heterozygous truncating mutation in RRM2B causes autosomal-dominant progressive external ophthalmoplegia with multiple mtDNA deletions.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19664747","citation_count":93,"is_preprint":false},{"pmid":"19667227","id":"PMC_19667227","title":"Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B.","date":"2009","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19667227","citation_count":91,"is_preprint":false},{"pmid":"14729598","id":"PMC_14729598","title":"In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/14729598","citation_count":82,"is_preprint":false},{"pmid":"17416930","id":"PMC_17416930","title":"p53R2-dependent ribonucleotide reduction provides deoxyribonucleotides in quiescent human fibroblasts in the absence of induced DNA damage.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17416930","citation_count":79,"is_preprint":false},{"pmid":"14583450","id":"PMC_14583450","title":"The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/14583450","citation_count":75,"is_preprint":false},{"pmid":"18504129","id":"PMC_18504129","title":"Mitochondrial DNA depletion syndrome due to mutations in the RRM2B gene.","date":"2008","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/18504129","citation_count":68,"is_preprint":false},{"pmid":"26733354","id":"PMC_26733354","title":"PYCR1 and PYCR2 Interact and Collaborate with RRM2B to Protect Cells from Overt Oxidative Stress.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26733354","citation_count":66,"is_preprint":false},{"pmid":"23107649","id":"PMC_23107649","title":"Adults with RRM2B-related mitochondrial disease have distinct clinical and molecular characteristics.","date":"2012","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23107649","citation_count":64,"is_preprint":false},{"pmid":"19015526","id":"PMC_19015526","title":"ATM-mediated serine 72 phosphorylation stabilizes ribonucleotide reductase small subunit p53R2 protein against MDM2 to DNA damage.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19015526","citation_count":55,"is_preprint":false},{"pmid":"17311703","id":"PMC_17311703","title":"Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer.","date":"2007","source":"Clinical colorectal cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17311703","citation_count":50,"is_preprint":false},{"pmid":"19138848","id":"PMC_19138848","title":"A novel homozygous RRM2B missense mutation in association with severe mtDNA depletion.","date":"2009","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/19138848","citation_count":50,"is_preprint":false},{"pmid":"17085643","id":"PMC_17085643","title":"Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells.","date":"2006","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17085643","citation_count":46,"is_preprint":false},{"pmid":"19010910","id":"PMC_19010910","title":"p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19010910","citation_count":44,"is_preprint":false},{"pmid":"18505925","id":"PMC_18505925","title":"Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells.","date":"2008","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/18505925","citation_count":44,"is_preprint":false},{"pmid":"19899807","id":"PMC_19899807","title":"Mechanism of inactivation of human ribonucleotide reductase with p53R2 by gemcitabine 5'-diphosphate.","date":"2009","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19899807","citation_count":44,"is_preprint":false},{"pmid":"19616983","id":"PMC_19616983","title":"A novel mutation of the RRM2B gene in an infant with early fatal encephalomyopathy, central hypomyelination, and tubulopathy.","date":"2009","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19616983","citation_count":44,"is_preprint":false},{"pmid":"21216934","id":"PMC_21216934","title":"p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest.","date":"2011","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/21216934","citation_count":43,"is_preprint":false},{"pmid":"24486301","id":"PMC_24486301","title":"The roles of p53R2 in cancer progression based on the new function of mutant p53 and cytoplasmic p21.","date":"2014","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24486301","citation_count":42,"is_preprint":false},{"pmid":"25086499","id":"PMC_25086499","title":"Akt and p53R2, partners that dictate the progression and invasiveness of cancer.","date":"2014","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/25086499","citation_count":41,"is_preprint":false},{"pmid":"17210678","id":"PMC_17210678","title":"Ribonucleotide reductase small subunit p53R2 facilitates p21 induction of G1 arrest under UV irradiation.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17210678","citation_count":41,"is_preprint":false},{"pmid":"18760875","id":"PMC_18760875","title":"Regulation of p53R2 and its role as potential target for cancer therapy.","date":"2008","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/18760875","citation_count":40,"is_preprint":false},{"pmid":"15890238","id":"PMC_15890238","title":"Silencing of the p53R2 gene by RNA interference inhibits growth and enhances 5-fluorouracil sensitivity of oral cancer cells.","date":"2004","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15890238","citation_count":37,"is_preprint":false},{"pmid":"21378381","id":"PMC_21378381","title":"Kearns-Sayre syndrome caused by defective R1/p53R2 assembly.","date":"2011","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21378381","citation_count":37,"is_preprint":false},{"pmid":"15655547","id":"PMC_15655547","title":"The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma.","date":"2005","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15655547","citation_count":37,"is_preprint":false},{"pmid":"19728742","id":"PMC_19728742","title":"2.6 A X-ray crystal structure of human p53R2, a p53-inducible ribonucleotide reductase .","date":"2009","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19728742","citation_count":36,"is_preprint":false},{"pmid":"16247478","id":"PMC_16247478","title":"Transcriptional responses to ionizing radiation reveal that p53R2 protects against radiation-induced mutagenesis in human lymphoblastoid cells.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16247478","citation_count":35,"is_preprint":false},{"pmid":"16488986","id":"PMC_16488986","title":"Structurally dependent redox property of ribonucleotide reductase subunit p53R2.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16488986","citation_count":34,"is_preprint":false},{"pmid":"23139867","id":"PMC_23139867","title":"RRM2B suppresses activation of the oxidative stress pathway and is up-regulated by p53 during senescence.","date":"2012","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/23139867","citation_count":33,"is_preprint":false},{"pmid":"24947616","id":"PMC_24947616","title":"Tumor suppressor FOXO3 regulates ribonucleotide reductase subunit RRM2B and impacts on survival of cancer patients.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24947616","citation_count":33,"is_preprint":false},{"pmid":"21297166","id":"PMC_21297166","title":"Deoxyribonucleotide metabolism in cycling and resting human fibroblasts with a missense mutation in p53R2, a subunit of ribonucleotide reductase.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21297166","citation_count":31,"is_preprint":false},{"pmid":"12565178","id":"PMC_12565178","title":"Expression of p53R2, newly p53 target in oral normal epithelium, epithelial dysplasia and squamous cell carcinoma.","date":"2003","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/12565178","citation_count":30,"is_preprint":false},{"pmid":"15723268","id":"PMC_15723268","title":"Rapid development of glomerular injury and renal failure in mice lacking p53R2.","date":"2005","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/15723268","citation_count":30,"is_preprint":false},{"pmid":"21951382","id":"PMC_21951382","title":"Exome sequencing identifies a novel missense variant in RRM2B associated with autosomal recessive progressive external ophthalmoplegia.","date":"2011","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/21951382","citation_count":30,"is_preprint":false},{"pmid":"11920641","id":"PMC_11920641","title":"Expression and mutation analyses of P53R2, a newly identified p53 target for DNA repair in human gastric carcinoma.","date":"2002","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11920641","citation_count":27,"is_preprint":false},{"pmid":"19398949","id":"PMC_19398949","title":"Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2.","date":"2009","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/19398949","citation_count":27,"is_preprint":false},{"pmid":"16619496","id":"PMC_16619496","title":"P53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer.","date":"2006","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16619496","citation_count":27,"is_preprint":false},{"pmid":"16206288","id":"PMC_16206288","title":"Disruption of the p53-p53r2 DNA repair system in ulcerative colitis contributes to colon tumorigenesis.","date":"2006","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16206288","citation_count":26,"is_preprint":false},{"pmid":"22954457","id":"PMC_22954457","title":"Akt phosphorylation in human chondrocytes is regulated by p53R2 in response to mechanical stress.","date":"2012","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/22954457","citation_count":25,"is_preprint":false},{"pmid":"31266802","id":"PMC_31266802","title":"Glutathione-glutaredoxin is an efficient electron donor system for mammalian p53R2-R1-dependent ribonucleotide reductase.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31266802","citation_count":25,"is_preprint":false},{"pmid":"23643536","id":"PMC_23643536","title":"Chromosomal instability triggered by Rrm2b loss leads to IL-6 secretion and plasmacytic neoplasms.","date":"2013","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/23643536","citation_count":23,"is_preprint":false},{"pmid":"31632084","id":"PMC_31632084","title":"miR-942 promotes proliferation and metastasis of hepatocellular carcinoma cells by inhibiting RRM2B.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31632084","citation_count":21,"is_preprint":false},{"pmid":"33868369","id":"PMC_33868369","title":"RRM2B Is Frequently Amplified Across Multiple Tumor Types: Implications for DNA Repair, Cellular Survival, and Cancer Therapy.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33868369","citation_count":20,"is_preprint":false},{"pmid":"16376858","id":"PMC_16376858","title":"Characterization of enzymatic properties of human ribonucleotide reductase holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16376858","citation_count":20,"is_preprint":false},{"pmid":"26796884","id":"PMC_26796884","title":"Novel regulators and molecular mechanisms of p53R2 and its disease relevance.","date":"2016","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/26796884","citation_count":18,"is_preprint":false},{"pmid":"26089597","id":"PMC_26089597","title":"RRM2B-Mediated Regulation of Mitochondrial Activity and Inflammation under Oxidative Stress.","date":"2015","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/26089597","citation_count":18,"is_preprint":false},{"pmid":"17115699","id":"PMC_17115699","title":"Circular dichroism and magnetic circular dichroism studies of the active site of p53R2 from human and mouse: iron binding and nature of the biferrous site relative to other ribonucleotide reductases.","date":"2006","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17115699","citation_count":18,"is_preprint":false},{"pmid":"17671702","id":"PMC_17671702","title":"Improvement in radiosensitivity using small interfering RNA targeting p53R2 in esophageal squamous cell carcinoma.","date":"2007","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/17671702","citation_count":16,"is_preprint":false},{"pmid":"21640705","id":"PMC_21640705","title":"Ribonucleotide reductase subunit p53R2 regulates mitochondria homeostasis and function in KB and PC-3 cancer cells.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/21640705","citation_count":16,"is_preprint":false},{"pmid":"31462754","id":"PMC_31462754","title":"The natural history of infantile mitochondrial DNA depletion syndrome due to RRM2B deficiency.","date":"2019","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31462754","citation_count":16,"is_preprint":false},{"pmid":"19082948","id":"PMC_19082948","title":"Redox property of ribonucleotide reductase small subunit M2 and p53R2.","date":"2008","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/19082948","citation_count":16,"is_preprint":false},{"pmid":"18804405","id":"PMC_18804405","title":"Ribonucleotide reductase small subunit p53R2 promotes oral cancer invasion via the E-cadherin/beta-catenin pathway.","date":"2008","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18804405","citation_count":14,"is_preprint":false},{"pmid":"29241262","id":"PMC_29241262","title":"Phenotypic and Genotypic Heterogeneity of RRM2B Variants.","date":"2017","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/29241262","citation_count":13,"is_preprint":false},{"pmid":"24215511","id":"PMC_24215511","title":"Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.","date":"2013","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24215511","citation_count":13,"is_preprint":false},{"pmid":"18474260","id":"PMC_18474260","title":"Upregulation of the p53R2 ribonucleotide reductase subunit by nitric oxide.","date":"2008","source":"Nitric oxide : biology and chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18474260","citation_count":13,"is_preprint":false},{"pmid":"18197409","id":"PMC_18197409","title":"Reprimo 824 G>C and p53R2 4696 C>G single nucleotide polymorphisms and colorectal cancer: a case-control disease association study.","date":"2008","source":"International journal of colorectal disease","url":"https://pubmed.ncbi.nlm.nih.gov/18197409","citation_count":12,"is_preprint":false},{"pmid":"24382854","id":"PMC_24382854","title":"Infantile peripheral neuropathy, deafness, and proximal tubulopathy associated with a novel mutation of the RRM2B gene: case study.","date":"2013","source":"Croatian medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/24382854","citation_count":12,"is_preprint":false},{"pmid":"27866984","id":"PMC_27866984","title":"p53R2 regulates thioredoxin reductase activity through interaction with TrxR2.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27866984","citation_count":10,"is_preprint":false},{"pmid":"31519977","id":"PMC_31519977","title":"Rrm2b deletion causes mitochondrial metabolic defects in renal tubules.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31519977","citation_count":10,"is_preprint":false},{"pmid":"21194559","id":"PMC_21194559","title":"Molecular analysis and functions of p53R2 in zebrafish.","date":"2010","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/21194559","citation_count":9,"is_preprint":false},{"pmid":"35756861","id":"PMC_35756861","title":"A novel RRM2B mutation associated with mitochondrial DNA depletion syndrome.","date":"2022","source":"Molecular genetics and metabolism reports","url":"https://pubmed.ncbi.nlm.nih.gov/35756861","citation_count":9,"is_preprint":false},{"pmid":"22895183","id":"PMC_22895183","title":"MEK2 regulates ribonucleotide reductase activity through functional interaction with ribonucleotide reductase small subunit p53R2.","date":"2012","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/22895183","citation_count":9,"is_preprint":false},{"pmid":"27382207","id":"PMC_27382207","title":"Differential Expressions of p53, p53R2, hRRM2 and PBR in Chronic Lymphocytic Leukemia: A Correlation with Intracellular Cholesterol.","date":"2015","source":"Indian journal of clinical biochemistry : IJCB","url":"https://pubmed.ncbi.nlm.nih.gov/27382207","citation_count":9,"is_preprint":false},{"pmid":"25878246","id":"PMC_25878246","title":"Caspase-dependent Proteolysis of Human Ribonucleotide Reductase Small Subunits R2 and p53R2 during Apoptosis.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25878246","citation_count":8,"is_preprint":false},{"pmid":"30439532","id":"PMC_30439532","title":"A homozygous variant in RRM2B is associated with severe metabolic acidosis and early neonatal death.","date":"2018","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30439532","citation_count":7,"is_preprint":false},{"pmid":"32775440","id":"PMC_32775440","title":"Prediction of the Impact of Deleterious Nonsynonymous Single Nucleotide Polymorphisms on the Human RRM2B Gene: A Molecular Modeling Study.","date":"2020","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/32775440","citation_count":7,"is_preprint":false},{"pmid":"30909120","id":"PMC_30909120","title":"Congenital cochlear deafness in mitochondrial diseases related to RRM2B and SERAC1 gene defects. A study of the mitochondrial patients of the CMHI hospital in Warsaw, Poland.","date":"2019","source":"International journal of pediatric otorhinolaryngology","url":"https://pubmed.ncbi.nlm.nih.gov/30909120","citation_count":7,"is_preprint":false},{"pmid":"11682647","id":"PMC_11682647","title":"Polymorphic insertion of additional repeat within an area of direct 8 bp tandem repeats in the 5'-untranslated region of the p53R2 gene and cancer risk.","date":"2001","source":"Mutagenesis","url":"https://pubmed.ncbi.nlm.nih.gov/11682647","citation_count":7,"is_preprint":false},{"pmid":"28482374","id":"PMC_28482374","title":"Novel RRM2B Mutation and Severe Mitochondrial DNA Depletion: Report of 2 Cases and Review of the Literature.","date":"2017","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/28482374","citation_count":6,"is_preprint":false},{"pmid":"14707445","id":"PMC_14707445","title":"Infrequent alteration in the p53R2 gene in human transitional cell carcinoma of the urinary tract.","date":"2004","source":"Pathobiology : journal of immunopathology, molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14707445","citation_count":5,"is_preprint":false},{"pmid":"29057303","id":"PMC_29057303","title":"RRM2B: An oxygen-requiring protein with a role in hypoxia.","date":"2017","source":"Molecular & cellular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29057303","citation_count":5,"is_preprint":false},{"pmid":"12202622","id":"PMC_12202622","title":"The discovery and confirmation of single nucleotide polymorphisms in the human p53R2 gene by EST database analysis.","date":"2002","source":"Mutagenesis","url":"https://pubmed.ncbi.nlm.nih.gov/12202622","citation_count":5,"is_preprint":false},{"pmid":"32827185","id":"PMC_32827185","title":"Renal dysfunction, rod-cone dystrophy, and sensorineural hearing loss caused by a mutation in RRM2B.","date":"2020","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/32827185","citation_count":4,"is_preprint":false},{"pmid":"32931159","id":"PMC_32931159","title":"The single nucleotide variant at c.662A>G in human RRM2B is a loss-of-function mutation.","date":"2020","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32931159","citation_count":4,"is_preprint":false},{"pmid":"16127747","id":"PMC_16127747","title":"Novel genetic variations of the p53R2 gene in patients with colorectal adenoma and controls.","date":"2005","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/16127747","citation_count":4,"is_preprint":false},{"pmid":"40244665","id":"PMC_40244665","title":"RRM2B deficiency causes dATP and dGTP depletion through enhanced degradation and slower synthesis.","date":"2025","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/40244665","citation_count":3,"is_preprint":false},{"pmid":"37620447","id":"PMC_37620447","title":"Targeting CK2-mediated phosphorylation of p53R2 sensitizes BRCA-proficient cancer cells to PARP inhibitors.","date":"2023","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/37620447","citation_count":3,"is_preprint":false},{"pmid":"34599703","id":"PMC_34599703","title":"Ribonucleotide reductase: In-vitro S-glutathionylation of R2 and p53R2 subunits of mammalian class I ribonucleotide reductase protein.","date":"2021","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/34599703","citation_count":2,"is_preprint":false},{"pmid":"36959467","id":"PMC_36959467","title":"Identification of two novel RRM2B variants associated with autosomal recessive progressive external ophthalmoplegia in a family with pseudodominant inheritance pattern.","date":"2023","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36959467","citation_count":2,"is_preprint":false},{"pmid":"22884950","id":"PMC_22884950","title":"Synergism between clofarabine and decitabine through p53R2: a pharmacodynamic drug-drug interaction modeling.","date":"2012","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/22884950","citation_count":2,"is_preprint":false},{"pmid":"37419428","id":"PMC_37419428","title":"Effect of siRNA-mediated silencing of p53R2 gene on sensitivity of T-ALL cellsto Daunorubicin.","date":"2023","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/37419428","citation_count":1,"is_preprint":false},{"pmid":"24861915","id":"PMC_24861915","title":"Investigation of the association of hRRM1 and p53R2 gene polymorphisms in head and neck squamous cell carcinomas.","date":"2014","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24861915","citation_count":1,"is_preprint":false},{"pmid":"41092345","id":"PMC_41092345","title":"Genetic dissection of Huntington's disease modification by variation at RRM2B.","date":"2025","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41092345","citation_count":0,"is_preprint":false},{"pmid":"38737634","id":"PMC_38737634","title":"Case Report: A novel RRM2B variant in a Chinese infant with mitochondrial DNA depletion syndrome and collective analyses of RRM2B variants for disease etiology.","date":"2024","source":"Frontiers in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/38737634","citation_count":0,"is_preprint":false},{"pmid":"38502357","id":"PMC_38502357","title":"Creatine kinase elevation in chronic hepatitis B patients with telbivudine therapy: influence of telbivudine plasma concentration and single nucleotide polymorphisms of TK2, RRM2B, and NME4.","date":"2024","source":"European journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38502357","citation_count":0,"is_preprint":false},{"pmid":"40211788","id":"PMC_40211788","title":"Deoxynucleoside supplementation ameliorates the disease associated phenotypes in a zebrafish model of RRM2B mtDNA depletion syndrome.","date":"2025","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40211788","citation_count":0,"is_preprint":false},{"pmid":"34964961","id":"PMC_34964961","title":"[Clinical characteristics and genetic analysis of a Chinese pedigree affected with mitochondrial DNA depletion syndrome due to compound heterozygous variants of RRM2B gene].","date":"2022","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34964961","citation_count":0,"is_preprint":false},{"pmid":"42031709","id":"PMC_42031709","title":"Roles of RRM2 and RRM2B in pyrimidine stress responses and differentiation of acute myeloid leukemia cells.","date":"2026","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/42031709","citation_count":0,"is_preprint":false},{"pmid":"42262096","id":"PMC_42262096","title":"Harmane induces apoptosis through RRM2B and suppresses colorectal cancer progression.","date":"2026","source":"mSystems","url":"https://pubmed.ncbi.nlm.nih.gov/42262096","citation_count":0,"is_preprint":false},{"pmid":"41766080","id":"PMC_41766080","title":"A Novel Truncating Pathogenic Variant in RRM2B in a Kurdish Family With Autosomal-Dominant Chronic Progressive External Ophthalmoplegia Plus (PEOA5).","date":"2026","source":"Journal of clinical neuromuscular disease","url":"https://pubmed.ncbi.nlm.nih.gov/41766080","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.07.03.662954","title":"Gain of Function p53 mutant R273H confers distinct methylation profiles and consequent partial or full EMT states to colon tumour","date":"2025-07-05","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.03.662954","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.09.647913","title":"A Dual-Action Liposome-Peptide Formulation Synergistically Counteracts A Gain-of-Function p53 Mutant","date":"2025-04-15","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.09.647913","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.17.24312688","title":"Causal associations between plasma proteins and prostate cancer: a Proteome-Wide Mendelian Randomization","date":"2024-09-18","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.17.24312688","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.06.606802","title":"Patient-specific gene networks reveal novel subtypes and predictive biomarkers in lung cancer","date":"2024-08-08","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.06.606802","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49293,"output_tokens":8298,"usd":0.136175,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17881,"output_tokens":7377,"usd":0.136915,"stage2_stop_reason":"end_turn"},"total_usd":0.27309,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"Recombinant human and mouse p53R2 proteins contain an iron-tyrosyl free radical center and form an active ribonucleotide reductase (RNR) complex with the R1 protein, demonstrating that R1 is the functional partner of p53R2 and that the R1-p53R2 complex can supply resting cells with deoxyribonucleotides for DNA repair.\",\n      \"method\": \"In vitro reconstitution of RNR activity with purified recombinant proteins; EPR spectroscopy to detect iron-tyrosyl radical; UV irradiation of serum-starved G0/G1 mouse fibroblasts with R1 promoter-luciferase reporter\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro reconstitution of enzymatic activity with purified proteins, EPR spectroscopy for radical center, and cell-based functional validation in a single rigorous study\",\n      \"pmids\": [\"11517226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"p53R2 protein accumulates in the nucleus after DNA damage (gamma-irradiation), whereas R2 remains cytoplasmic; nuclear accumulation of p53R2 correlates with elevated RNR-dependent DNA synthesis activity after DNA damage. A point mutation in p53R2 in the HCT116 cancer cell line abolishes RNR activity, leading to enhanced p53AIP1-mediated apoptosis.\",\n      \"method\": \"Western blot of nuclear/cytoplasmic fractions; RNR activity assay; site-directed mutagenesis; gamma-irradiation of cells\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — subcellular fractionation with functional RNR activity assay and mutagenesis, single lab study\",\n      \"pmids\": [\"11719458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Rrm2b-null mice show severe dNTP pool attenuation in mouse embryonic fibroblasts under oxidative stress, increased spontaneous mutation frequency in kidneys, p53 activation, and early death from renal failure, establishing that p53R2 is required in vivo for dNTP supply for DNA repair in resting cells.\",\n      \"method\": \"Rrm2b knockout mouse generation; dNTP pool measurement; TUNEL staining; spontaneous mutation assay; p53 target gene transcription analysis\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with multiple orthogonal phenotypic and biochemical readouts, published in high-impact journal\",\n      \"pmids\": [\"12858174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Wild-type p53 directly interacts with both p53R2 and hRRM2 subunits (but not hRRM1) in co-immunoprecipitation experiments. After UV irradiation, p53R2 and hRRM2 dissociate from p53 and translocate with hRRM1 to the nucleus, where increased RNR activity is detected. This nuclear translocation and p53 dissociation are deficient in cells expressing mutant p53.\",\n      \"method\": \"Co-immunoprecipitation; confocal microscopy for colocalization; in vivo RNR activity assay; UV irradiation\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and confocal microscopy with functional RNR activity assay, single lab\",\n      \"pmids\": [\"12615712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Purified recombinant p53R2 forms active RNR with hRRM1 via a C-terminal heptapeptide binding site shared with hRRM2, but with 4.76-fold lower binding affinity for hRRM1 than hRRM2. p53R2-containing RNR has ~20–50% lower kinetic activity than hRRM2-containing RNR. p53R2 is 158-fold more susceptible to the iron chelator deferoxamine mesylate than hRRM2, whereas it is 2.5-fold less sensitive to hydroxyurea; the iron center and tyrosyl radical are required for RNR activity.\",\n      \"method\": \"In vitro [3H]CDP reduction assay; synthetic heptapeptide competition assay; atomic absorption spectrometry for iron content; EPR for tyrosyl radical; deferoxamine and hydroxyurea inhibition studies\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic reconstitution with multiple inhibitor and binding assays, rigorous biochemical characterization, single lab\",\n      \"pmids\": [\"14729598\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Loss-of-function mutations in RRM2B (nonsense, missense, splice-site, in-frame deletions) cause severe mitochondrial DNA (mtDNA) depletion in humans, and Rrm2b-/- mice show severe mtDNA depletion in multiple tissues, demonstrating that p53R2 is required for dNTP supply for mtDNA synthesis.\",\n      \"method\": \"RRM2B sequencing in human patients; Southern blot/quantitative PCR for mtDNA copy number in human tissues and Rrm2b-/- mouse tissues\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human genetics plus mouse knockout model, replicated across multiple families and tissues, independently replicated by subsequent studies\",\n      \"pmids\": [\"17486094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"In quiescent human fibroblasts lacking R2, the R1-p53R2 complex supports a complete de novo deoxyribonucleotide synthesis pathway (including thymidylate synthesis), with the primary function of providing dNTPs for mitochondrial DNA replication rather than nuclear DNA synthesis.\",\n      \"method\": \"Isotope incorporation with [5-3H]cytidine, [6-3H]deoxycytidine, [CH3-3H]thymidine in confluent quiescent human fibroblasts; measurement of dNTP pools and nucleoside export\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct isotope flux measurements in quiescent cells with multiple tracers, rigorous biochemical assay, single lab\",\n      \"pmids\": [\"17416930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"p53R2 physically interacts with p21 in vivo; the N-terminal region (aa 1–113) of p53R2 interacts with the N-terminal region (aa 1–93) of p21. In response to UV, p53R2 dissociates from p21, facilitates nuclear accumulation of p21, and RNR activity increases, suggesting p53R2 cooperates with p21 during G1 DNA repair arrest.\",\n      \"method\": \"Co-immunoprecipitation; mammalian two-hybrid assay; confocal microscopy; UV irradiation; RNR activity assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and mammalian two-hybrid defining interaction domain, with functional RNR assay, single lab\",\n      \"pmids\": [\"17210678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ATM phosphorylates p53R2 at Ser72 within 30 minutes of genotoxic stress, and p53R2 and its partner RRM1 are associated with ATM in vivo. Ser72 phosphorylation stabilizes p53R2 by preventing MDM2-mediated ubiquitination and degradation; the S72A mutant shows hyperubiquitination, reduced stability, and impaired DNA damage resistance.\",\n      \"method\": \"In vivo co-immunoprecipitation of p53R2/RRM1 with ATM; site-directed mutagenesis (S72A); ubiquitination assay; Western blot for protein stability; ATM kinase inhibitor treatment\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mutagenesis with ubiquitination assay and Co-IP defining writer (ATM) and reader/eraser (MDM2) in a single rigorous study\",\n      \"pmids\": [\"19015526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"A heterozygous truncating mutation in RRM2B (p.R327X) removes 25 highly conserved C-terminal amino acids essential for interaction with the R1 subunit of ribonucleotide reductase, causing autosomal-dominant progressive external ophthalmoplegia with multiple mtDNA deletions, consistent with a dominant-negative or gain-of-function mechanism.\",\n      \"method\": \"Genetic linkage mapping; RRM2B sequencing; nonsense-mediated decay analysis; protein truncation assessment; family segregation analysis\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and molecular characterization, functional inference from C-terminal domain loss, two independent families, single lab\",\n      \"pmids\": [\"19664747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Gemcitabine 5'-diphosphate (F2CDP) is a substoichiometric inactivator of the human RNR alpha/p53R2 (beta') complex; inactivation results in covalent attachment of ~0.5 equiv sugar to alpha subunit and release of cytosine, with cross-linking observed by SDS-PAGE. Active site mutants (C444S/A, C218S/A, E431Q/D) do not bind the sugar label, establishing that inactivation requires the catalytic active site of the alpha (R1) subunit.\",\n      \"method\": \"In vitro [1'-3H]-F2CDP and [5-3H]-F2CDP radiolabel incorporation; SDS-PAGE; size exclusion chromatography; active site mutagenesis of alpha subunit; Sephadex G-50 reisolation\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with radiolabeled substrate and active-site mutagenesis defining the mechanism of inactivation, single rigorous study\",\n      \"pmids\": [\"19899807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The 2.6 Å X-ray crystal structure of human p53R2 reveals monomers with mono- and binuclear iron occupancy; pronounced structural differences at three regions from hRRM2 explain differences in iron assimilation, mobility/accessibility of the radical iron center, and radical transfer pathways between the two enzymes.\",\n      \"method\": \"X-ray crystallography at 2.6 Å resolution\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with functional interpretation, definitive structural determination\",\n      \"pmids\": [\"19728742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"p53R2 interacts physically with MEK2 (ERK kinase 2) in co-immunoprecipitation and immunofluorescence assays; the p53R2 segment aa 161–206 is critical for this interaction. p53R2 negatively modulates serum-induced MEK-ERK signaling: knockdown of p53R2 augments MEK1/2 and ERK1/2 phosphorylation, while overexpression attenuates it. MEK2 is required for p53R2 knockdown-enhanced invasion and anchorage-independent growth.\",\n      \"method\": \"Co-immunoprecipitation; immunofluorescence; siRNA knockdown; overexpression; phosphorylation assay by Western blot; Matrigel invasion assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP defining interaction domain plus functional epistasis by siRNA/overexpression, single lab\",\n      \"pmids\": [\"19398949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In quiescent (but not cycling) patient fibroblasts carrying a lethal missense mutation in p53R2, mtDNA synthesis is defective after ethidium bromide depletion and recovery, and UV-induced DNA repair is impaired (delayed dsDNA recovery, prolonged γH2AX phosphorylation). Supplementation with deoxynucleosides restored dNTP pools, mtDNA synthesis, and DNA repair, confirming that p53R2-dependent ribonucleotide reduction is specifically required for mtDNA maintenance and DNA repair in quiescent cells.\",\n      \"method\": \"Ethidium bromide depletion/recovery assay for mtDNA; fluorometric analysis of DNA unwinding (FADU) for repair; γH2AX Western blot; dNTP pool measurement; deoxynucleoside supplementation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal functional assays in patient cells, rescue by deoxynucleoside supplementation provides mechanistic proof, single lab with rigorous controls\",\n      \"pmids\": [\"22847445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In Kearns-Sayre syndrome caused by two novel RRM2B missense mutations, Blue-native PAGE demonstrates reduced heterotetrameric R1/p53R2 RNR levels despite normal steady-state p53R2 on Western blot, establishing that defective R1/p53R2 RNR assembly is a disease mechanism.\",\n      \"method\": \"Western blot; Blue-native polyacrylamide gel electrophoresis (BN-PAGE); RRM2B DNA sequencing\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — BN-PAGE directly demonstrating impaired protein complex assembly in patient cells, single lab\",\n      \"pmids\": [\"21378381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Purified recombinant p53R2 has catalase activity (breaks down H2O2) and reduces intracellular ROS while protecting mitochondrial membrane potential against oxidative stress, in contrast to hRRM2 which increases ROS. Site-directed mutagenesis identified Y331, Y285, Y49, and Y241 as critical residues for antioxidant activity; these mutations also negatively correlated with RNR enzymatic activity.\",\n      \"method\": \"Cell-free ROS assay with carboxy-H2DCFDA; catalase activity assay with purified protein; mitochondrial membrane potential assay; site-directed mutagenesis; overexpression in cells\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro catalase assay with purified protein plus mutagenesis defining critical residues, complemented by cell-based assays, single rigorous study\",\n      \"pmids\": [\"16488986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Rrm2b gene loss causes severe numerical and structural chromosomal abnormalities leading to ATM activation, which induces IKKγ/NEMO phosphorylation at pSer85, activating IKK and NF-κB, resulting in sustained IL-6 expression and constitutive STAT3 activation. Genetic ablation of IL-6 suppressed STAT3 and delayed disease onset in Rrm2b-/- mice, establishing this pathway as causal for inflammation-associated tumorigenesis.\",\n      \"method\": \"Rrm2b knockout mouse; cytogenetic analysis; ATM and IKK phosphorylation assays; NF-κB and STAT3 activation; IL-6 ELISA; IL-6 genetic knockout cross; mouse lifespan analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in vivo (IL-6 KO rescue), biochemical pathway mapping, multiple orthogonal methods in a single study\",\n      \"pmids\": [\"23643536\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"p53R2 overexpression reduces intracellular ROS, maintains mtDNA content, and supports cytochrome c oxidase activity and ATP synthesis; siRNA knockdown of p53R2 reduces mtDNA content, impairs mitochondrial function (ATP synthesis, COX activity, membrane potential), and increases ROS, establishing a role for p53R2 in mitochondrial homeostasis beyond dNTP synthesis.\",\n      \"method\": \"siRNA knockdown; overexpression; mtDNA quantification by PCR; ATP synthesis assay; cytochrome c oxidase activity assay; mitochondrial membrane potential assay; ROS measurement\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays in siRNA KD and OE cells, single lab, no in vivo validation\",\n      \"pmids\": [\"21640705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"RRM2B is highly induced in a p53-dependent manner during senescence; silencing RRM2B increases ROS, induces mitochondrial membrane depolarization, and causes premature senescence in a p38MAPK- and p53-dependent manner. Senescence is accelerated in Rrm2b-deficient MEFs.\",\n      \"method\": \"RRM2B siRNA knockdown in IMR90 fibroblasts; senescence assays; ROS measurement; mitochondrial membrane potential assay; p38MAPK inhibitor treatment; Rrm2b-/- MEFs\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown plus genetic KO MEFs with multiple pathway inhibitors, single lab\",\n      \"pmids\": [\"23139867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MEK2 regulates RNR activity through a direct interaction with p53R2; the MEK2 segment aa 65–171 is critical for p53R2 binding. Inhibition of MEK2 (by siRNA or pharmacological inhibitor) dramatically decreases serum-stimulated RNR activity, and p53R2 siRNA (but not R2 siRNA) inhibits this activity, indicating specific MEK2-p53R2 regulation. Ionizing radiation activates MEK1/2 and increases RNR activity, which is attenuated by MEK2 or p53R2 siRNA.\",\n      \"method\": \"Co-immunoprecipitation; MEK2 siRNA; MEK inhibitor; RNR activity assay; ionizing radiation\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain mapping and functional RNR assay, confirmed with siRNA and pharmacological inhibitor, single lab\",\n      \"pmids\": [\"22895183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PYCR1 and PYCR2 were identified by mass spectrometry as components of RRM2B complexes. Silencing of both PYCR1 and PYCR2 abolished the antioxidant activity of RRM2B overexpression, demonstrating a functional collaboration between RRM2B, PYCR1, and PYCR2 in protecting cells from oxidative stress.\",\n      \"method\": \"Large-scale Flag-tagged RRM2B complex purification; mass spectrometry; shRNA silencing of PYCR1/PYCR2; oxidative stress assays; mitochondrial network analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS-based interactome followed by functional shRNA validation, single lab\",\n      \"pmids\": [\"26733354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FOXO3 directly binds to the RRM2B promoter and transcriptionally activates RRM2B expression at RNA and protein levels independently of p53, establishing FOXO3 as a novel p53-independent regulator of RRM2B.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP); promoter luciferase assay; FOXO3 overexpression; Western blot and RT-PCR; cancer cell proliferation assay\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and promoter assay establishing direct transcriptional regulation, single lab\",\n      \"pmids\": [\"24947616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The glutathione-glutaredoxin (GSH-Grx) system is 4–6 times more catalytically efficient than the thioredoxin-1 (Trx1) system as electron donor for mammalian R1-p53R2 RNR, with Vmax for Grx strongly dependent on GSH concentration. GSH reductase is essential for this reaction. This identifies the C-terminal swinging-arm dithiol/disulfide of R1 as having a crucial catalytic role in reduction for p53R2-containing RNR.\",\n      \"method\": \"In vitro RNR activity assay with mouse R1-p53R2; comparison of Grx vs Trx1 electron donor systems; Vmax/Km kinetic measurements; GSH reductase dependency assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with kinetic characterization of electron donor systems, rigorous biochemical study, single lab\",\n      \"pmids\": [\"31266802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"p53R2 interacts with mitochondrial thioredoxin reductase 2 (TrxR2) and stimulates TrxR enzymatic activity in vitro. TrxR2 activity is significantly lower in p53R2 knockdown cells and increased upon p53R2 overexpression in a p53-independent manner; p53R2 knockdown also suppresses UV-induced TrxR activity.\",\n      \"method\": \"Co-immunoprecipitation; in vitro TrxR activity assay; siRNA knockdown; overexpression; UV irradiation\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with in vitro activity assay and cell-based knockdown/overexpression, single lab\",\n      \"pmids\": [\"27866984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"During apoptosis, p53R2 is cleaved in a caspase-dependent manner (by caspase-3 and caspase-8) between Asp342 and Asn343, releasing a C-terminal 9-residue peptide containing the conserved heptapeptide essential for R1 binding, rendering the cleaved p53R2 inactive. R1 is not degraded during apoptosis.\",\n      \"method\": \"Cell treatment with Bcr-Abl inhibitors and TNF-α/cycloheximide; Western blot for cleavage products; in vitro cleavage by purified caspase-3 and -8; caspase-specific siRNA knockdown; cleavage site mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified caspases defining the cleavage site, complemented by cell-based siRNA epistasis, single rigorous study\",\n      \"pmids\": [\"25878246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Circular dichroism and magnetic circular dichroism spectroscopy of p53R2 revealed a biferrous active site with one five-coordinate and one four-coordinate iron weakly antiferromagnetically coupled through mu-1,3-carboxylate bridges; both human and mouse p53R2 have high Fe(II) affinity, distinct from mouse R2, potentially reflecting differences in regulation of enzymatic activity.\",\n      \"method\": \"Circular dichroism (CD); magnetic circular dichroism (MCD); variable-temperature variable-field MCD; EPR spectroscopy; Fe(II) titration for metal binding affinity\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal spectroscopic methods (CD, MCD, VTVH-MCD, EPR) in a single rigorous study; definitive active site characterization\",\n      \"pmids\": [\"17115699\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CK2 (casein kinase II) phosphorylates p53R2 at Ser20, activating RNR for dNTP production. Loss of p53R2 impairs homologous recombination (HR) repair by reducing CtIP levels through dNTP shortage-induced ubiquitination of CtIP. Pharmacologic inhibition of CK2-mediated p53R2 Ser20 phosphorylation compromises HR repair in BRCA1/2-WT cancer cells and sensitizes them to PARP inhibitors.\",\n      \"method\": \"CK2 kinase assay; phospho-specific antibody; siRNA depletion of p53R2; ubiquitination assay for CtIP; HR repair reporter assay; PARP inhibitor sensitivity assay in vitro and in vivo\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinase identification with functional epistasis showing HR pathway placement, in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"37620447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"p53R2 (and R2) subunits of mammalian RNR can be S-glutathionylated in vitro, and the Grx1 system efficiently deglutathionylates the S-glutathionylated p53R2, suggesting S-glutathionylation as a redox regulatory mechanism for p53R2 activity.\",\n      \"method\": \"In vitro S-glutathionylation assay; Grx1-mediated deglutathionylation assay; Western blot with anti-glutathione antibody\",\n      \"journal\": \"Molecular biology reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — in vitro modification only, no functional activity assay after glutathionylation, single method, single lab\",\n      \"pmids\": [\"34599703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In Rrm2b knockout mouse tissues, RRM2B deficiency selectively depletes dATP and dGTP pools while dCTP and dTTP remain stable or increase. Mechanistically, this is attributed to preferred degradation of dATP and dGTP by the dNTPase SAMHD1 combined with lower RNR production rate of dATP.\",\n      \"method\": \"Rrm2b knockout mouse model; dNTP pool measurement in non-dividing tissues; SAMHD1 substrate preference analysis; comparison with hydroxyurea-treated controls\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with quantitative dNTP pool measurement and mechanistic attribution to SAMHD1, single lab but rigorous in vivo model\",\n      \"pmids\": [\"40244665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"In vitro reconstitution using eukaryotically expressed and purified hRRM1, hRRM2, and p53R2 confirmed that both hRRM2 and p53R2 interact with hRRM1 to form functional RNR holoenzyme; hRRM2 and p53R2 share the same binding site on hRRM1 (competitive C-terminal heptapeptide), but hRRM1 has higher affinity for hRRM2 than p53R2. ATP and dATP allosteric regulation of hRRM1 is independent of which small subunit is present.\",\n      \"method\": \"Eukaryotic expression and purification of RNR subunits; [3H]CDP reduction assay; synthetic C-terminal heptapeptide competition assay; allosteric regulation assay with ATP/dATP\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with kinetic and competition assays, replicated from prior in vitro work using eukaryotic system, single lab\",\n      \"pmids\": [\"16376858\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RRM2B (p53R2) encodes the small subunit of a ribonucleotide reductase (RNR) complex that pairs with the R1 catalytic subunit (RRM1) via a conserved C-terminal heptapeptide to form an active enzyme; the p53R2 monomer harbors an iron-tyrosyl radical center (structurally resolved at 2.6 Å) required for catalysis, is specifically induced by p53 in response to DNA damage and by FOXO3 independently of p53, is rapidly stabilized by ATM-mediated Ser72 phosphorylation (protecting it from MDM2-dependent ubiquitination) and activated by CK2-mediated Ser20 phosphorylation, is inactivated by caspase-3/8 cleavage at Asp342 during apoptosis, supplies dNTPs (preferentially dATP and dGTP) for nuclear DNA repair and mitochondrial DNA replication especially in quiescent/non-dividing cells, scavenges reactive oxygen species through a catalase-like activity requiring specific tyrosine residues, interacts with p21 and MEK2 to modulate cell cycle arrest and ERK signaling, collaborates with PYCR1/PYCR2 for antioxidant protection and with TrxR2 in mitochondria, and is reduced by the GSH-Grx electron donor system with higher efficiency than by thioredoxin; loss of RRM2B causes selective depletion of dATP and dGTP, mtDNA depletion syndrome, chromosomal instability leading to NF-κB/IL-6/STAT3 pathway activation, and early lethality in mice and humans.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RRM2B (p53R2) encodes the small subunit of a ribonucleotide reductase (RNR) that supplies deoxyribonucleotides for genome maintenance in resting and non-dividing cells, the function in which it is most critical [#0, #2, #6]. It harbors an iron-tyrosyl free radical center and pairs with the catalytic R1 subunit (RRM1) through a C-terminal heptapeptide—the same binding site used by the cycling-cell subunit R2 but with lower R1 affinity—to form an active holoenzyme [#0, #4, #29]. Crystallographic and spectroscopic studies define a biferrous active site whose iron assimilation and radical-transfer properties differ from R2, accounting for its distinct kinetic and inhibitor sensitivities [#11, #25]. In quiescent cells the R1–p53R2 complex drives a complete de novo dNTP synthesis pathway dedicated chiefly to mitochondrial DNA replication and DNA repair [#6, #13]; its loss selectively depletes dATP and dGTP, an asymmetry attributable to SAMHD1-mediated degradation and lower RNR output of these nucleotides [#28]. Expression is induced both by p53 and, independently, by FOXO3 binding the RRM2B promoter [#21], while the protein is acutely regulated post-translationally: ATM phosphorylates Ser72 to block MDM2-dependent ubiquitination and stabilize it after genotoxic stress [#8], CK2 phosphorylates Ser20 to activate dNTP production supporting CtIP-dependent homologous recombination [#26], and caspase-3/8 cleavage at Asp342 removes the R1-binding heptapeptide to inactivate the enzyme during apoptosis [#24]. Beyond nucleotide supply, p53R2 has intrinsic catalase-like antioxidant activity dependent on specific tyrosines, lowers ROS, and preserves mitochondrial membrane potential and function, acting with PYCR1/PYCR2 and stimulating mitochondrial TrxR2 [#15, #17, #20, #23]. It is reduced more efficiently by the glutathione-glutaredoxin system than by thioredoxin [#22]. Loss-of-function and dominant C-terminal RRM2B mutations cause human mitochondrial DNA depletion syndromes, progressive external ophthalmoplegia, and Kearns-Sayre syndrome through impaired R1/p53R2 RNR assembly and mtDNA maintenance [#5, #9, #14, #13], and in mice Rrm2b loss produces chromosomal instability that activates ATM–IKK–NF-κB–IL-6–STAT3 signaling driving inflammation-associated disease [#16].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established that p53R2 is a genuine RNR small subunit, resolving whether the p53-inducible protein had catalytic function rather than merely regulatory activity.\",\n      \"evidence\": \"In vitro reconstitution of RNR activity with purified recombinant p53R2 and R1, EPR detection of an iron-tyrosyl radical, and reporter assays in serum-starved fibroblasts\",\n      \"pmids\": [\"11517226\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define affinity differences from R2\", \"In vivo requirement not yet shown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Connected p53R2 to the DNA damage response by showing damage-induced nuclear accumulation and its requirement for RNR activity opposing apoptosis.\",\n      \"evidence\": \"Nuclear/cytoplasmic fractionation, RNR activity assay, and site-directed mutagenesis in gamma-irradiated cancer cells\",\n      \"pmids\": [\"11719458\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of nuclear import undefined\", \"Single cell-line mutation analysis\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrated in vivo that p53R2 is required for dNTP supply and genome stability in resting cells, linking its loss to mutation and organismal lethality.\",\n      \"evidence\": \"Rrm2b-null mice with dNTP pool, mutation frequency, TUNEL and p53 target readouts\",\n      \"pmids\": [\"12858174\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mitochondrial versus nuclear contribution not separated at this stage\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Placed p53R2 in a p53-dependent regulatory circuit by showing p53 sequesters it until DNA damage triggers dissociation and nuclear translocation with R1.\",\n      \"evidence\": \"Co-immunoprecipitation, confocal colocalization, and in vivo RNR assay after UV in WT versus mutant p53 cells\",\n      \"pmids\": [\"12615712\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding interface with p53 not mapped\", \"Single lab, reciprocal but not structural\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Quantified the biochemical distinction between p53R2 and R2, showing shared R1-binding heptapeptide but lower affinity, lower activity, and distinct iron-chelator/hydroxyurea sensitivities.\",\n      \"evidence\": \"In vitro CDP reduction, heptapeptide competition, atomic absorption, EPR, and inhibitor studies\",\n      \"pmids\": [\"14729598\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of affinity difference not resolved here\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Confirmed in a eukaryotic expression system that R2 and p53R2 compete for the same R1 site and that allosteric ATP/dATP regulation is subunit-independent.\",\n      \"evidence\": \"Reconstitution of purified eukaryotic subunits with CDP reduction, heptapeptide competition, and allosteric assays\",\n      \"pmids\": [\"16376858\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In-cell competition dynamics not addressed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Revealed an unexpected antioxidant function: p53R2 has catalase-like activity that lowers ROS and protects mitochondrial membrane potential, mapped to specific tyrosines.\",\n      \"evidence\": \"Cell-free ROS and catalase assays with purified protein, mitochondrial membrane potential assay, and tyrosine mutagenesis\",\n      \"pmids\": [\"16488986\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relationship between catalase and RNR activities mechanistically entangled via shared tyrosines\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Characterized the diiron active site spectroscopically, defining a biferrous center with high Fe(II) affinity distinct from R2.\",\n      \"evidence\": \"CD, MCD, VTVH-MCD, EPR, and Fe(II) titration\",\n      \"pmids\": [\"17115699\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of high Fe affinity for in vivo regulation inferred not tested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified mitochondrial DNA maintenance as a primary in vivo role, establishing RRM2B mutations as a cause of human mtDNA depletion.\",\n      \"evidence\": \"RRM2B sequencing in patients and mtDNA copy-number quantification in human tissues and Rrm2b-/- mice\",\n      \"pmids\": [\"17486094\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-type specificity of mtDNA depletion not fully resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed flux through the R1-p53R2 complex constitutes a complete de novo dNTP pathway in quiescent cells serving mtDNA replication.\",\n      \"evidence\": \"Isotope tracer incorporation in confluent quiescent human fibroblasts with dNTP pool and export measurement\",\n      \"pmids\": [\"17416930\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Salvage pathway interplay not quantified\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Linked p53R2 to cell cycle arrest machinery via a defined interaction with p21 modulating p21 nuclear accumulation during repair.\",\n      \"evidence\": \"Co-IP, mammalian two-hybrid domain mapping, and confocal microscopy with RNR assay after UV\",\n      \"pmids\": [\"17210678\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional significance for arrest not genetically tested\", \"Single lab\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined the ATM-MDM2 axis controlling p53R2 stability, explaining how genotoxic stress rapidly stabilizes the protein.\",\n      \"evidence\": \"ATM Co-IP, S72A mutagenesis, ubiquitination and protein stability assays with ATM inhibitor\",\n      \"pmids\": [\"19015526\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of phosphorylation-protected MDM2 interface unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Mapped the molecular consequence of a dominant C-terminal truncation, linking loss of R1 binding to autosomal-dominant PEO with mtDNA deletions.\",\n      \"evidence\": \"Linkage mapping, RRM2B sequencing, NMD and truncation analysis, family segregation\",\n      \"pmids\": [\"19664747\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Dominant-negative versus gain-of-function not biochemically distinguished\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Determined the human p53R2 crystal structure, explaining its distinct iron handling and radical transfer relative to R2.\",\n      \"evidence\": \"X-ray crystallography at 2.6 Å\",\n      \"pmids\": [\"19728742\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Holoenzyme R1-p53R2 complex structure not determined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined the mechanism by which gemcitabine diphosphate inactivates the alpha/p53R2 complex through covalent active-site modification.\",\n      \"evidence\": \"Radiolabeled F2CDP incorporation, SDS-PAGE crosslinking, and alpha-subunit active-site mutagenesis\",\n      \"pmids\": [\"19899807\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In-cell relevance to gemcitabine therapy not addressed\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Uncovered a non-canonical role linking p53R2 to MEK-ERK signaling and tumor cell invasion through a direct MEK2 interaction.\",\n      \"evidence\": \"Co-IP with domain mapping, immunofluorescence, siRNA/overexpression with invasion and anchorage-independent growth assays\",\n      \"pmids\": [\"19398949\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether this is RNR-dependent unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed that defective R1/p53R2 RNR holoenzyme assembly underlies disease, even when p53R2 protein levels appear normal.\",\n      \"evidence\": \"BN-PAGE of RNR complex with Western blot and sequencing in Kearns-Sayre patient cells\",\n      \"pmids\": [\"21378381\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural defect in assembly not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Provided mechanistic proof in patient cells that p53R2-dependent ribonucleotide reduction is specifically needed for mtDNA maintenance and repair in quiescence, rescuable by deoxynucleosides.\",\n      \"evidence\": \"Ethidium bromide depletion/recovery, FADU repair assay, γH2AX, dNTP pools, and deoxynucleoside supplementation\",\n      \"pmids\": [\"22847445\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Therapeutic durability of deoxynucleoside rescue not assessed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established a causal inflammatory pathway whereby Rrm2b loss-driven chromosomal instability activates ATM-IKK-NF-κB-IL-6-STAT3 signaling.\",\n      \"evidence\": \"Rrm2b knockout cytogenetics, phosphorylation assays, IL-6 ELISA, IL-6 genetic rescue, and lifespan analysis\",\n      \"pmids\": [\"23643536\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct sensing event linking instability to ATM not detailed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrated that p53R2 supports mitochondrial bioenergetics and homeostasis beyond dNTP supply.\",\n      \"evidence\": \"siRNA/overexpression with mtDNA quantification, ATP synthesis, COX activity, membrane potential and ROS assays\",\n      \"pmids\": [\"21640705\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vivo validation\", \"Secondary versus direct effects unresolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Linked p53R2 to senescence control, showing its silencing triggers premature senescence via ROS and p38MAPK/p53.\",\n      \"evidence\": \"siRNA in IMR90 fibroblasts and Rrm2b-/- MEFs with senescence, ROS, membrane potential assays and p38 inhibition\",\n      \"pmids\": [\"23139867\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Causality of ROS versus dNTP depletion not separated\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed MEK2 directly regulates RNR activity through p53R2, integrating mitogenic signaling with nucleotide production.\",\n      \"evidence\": \"Co-IP domain mapping, MEK2 siRNA/inhibitor, and RNR activity assays after serum or ionizing radiation\",\n      \"pmids\": [\"22895183\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which MEK2 binding alters RNR catalysis unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified FOXO3 as a p53-independent transcriptional activator of RRM2B, broadening its regulatory inputs.\",\n      \"evidence\": \"ChIP, promoter luciferase, FOXO3 overexpression with RT-PCR and Western blot\",\n      \"pmids\": [\"24947616\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological conditions invoking FOXO3 regulation not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined how apoptosis inactivates p53R2 through caspase-3/8 cleavage at Asp342 removing the R1-binding heptapeptide.\",\n      \"evidence\": \"In vitro cleavage with purified caspases, cleavage-site mapping, and caspase siRNA in apoptotic cells\",\n      \"pmids\": [\"25878246\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological impact of dNTP loss during apoptosis not quantified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified PYCR1/PYCR2 as functional partners required for p53R2-mediated antioxidant protection.\",\n      \"evidence\": \"Flag-RRM2B complex purification with mass spectrometry and PYCR1/2 shRNA with oxidative stress assays\",\n      \"pmids\": [\"26733354\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Biochemical mechanism of the collaboration unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed p53R2 interacts with and stimulates mitochondrial TrxR2, connecting it to the mitochondrial antioxidant system.\",\n      \"evidence\": \"Co-IP, in vitro TrxR activity assay, siRNA/overexpression, and UV stimulation\",\n      \"pmids\": [\"27866984\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of TrxR2 stimulation unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined the preferred electron-donor system for R1-p53R2, showing GSH-glutaredoxin is more efficient than thioredoxin.\",\n      \"evidence\": \"In vitro RNR activity kinetics comparing Grx and Trx1 systems with GSH reductase dependency\",\n      \"pmids\": [\"31266802\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In-cell reductant usage not measured\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Proposed S-glutathionylation as a redox regulatory modification of p53R2 reversed by Grx1.\",\n      \"evidence\": \"In vitro S-glutathionylation and Grx1 deglutathionylation with anti-glutathione Western blot\",\n      \"pmids\": [\"34599703\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No functional activity assay after glutathionylation\", \"In vitro only, single method\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined CK2-mediated Ser20 phosphorylation as an activating switch coupling p53R2 dNTP supply to CtIP stability and homologous recombination, with therapeutic implications for PARP inhibitors.\",\n      \"evidence\": \"CK2 kinase assay, phospho-specific antibody, p53R2 siRNA, CtIP ubiquitination, HR reporter, and PARP inhibitor sensitivity in vitro and in vivo\",\n      \"pmids\": [\"37620447\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct structural effect of Ser20 phosphorylation on RNR undefined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Explained why RRM2B loss selectively depletes dATP and dGTP, attributing the asymmetry to SAMHD1 degradation preference and lower RNR output.\",\n      \"evidence\": \"Rrm2b knockout mouse dNTP pool measurement in non-dividing tissues with SAMHD1 substrate analysis\",\n      \"pmids\": [\"40244665\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct in vivo demonstration of SAMHD1 epistasis not performed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the multiple post-translational and protein-interaction inputs (ATM/Ser72, CK2/Ser20, MEK2, p21, redox modifications) are integrated to tune p53R2 activity in specific physiological contexts, and the structure of the assembled R1-p53R2 holoenzyme, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No holoenzyme structure\", \"Integration of competing regulatory signals not modeled\", \"In-cell electron-donor and redox regulation not directly measured\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 4, 6, 29]},\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 4, 25]},\n      {\"term_id\": \"GO:0016209\", \"supporting_discovery_ids\": [15, 17]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 3]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 6]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [5, 17, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [0, 2, 13, 26]},\n      {\"term_id\": \"R-HSA-69306\", \"supporting_discovery_ids\": [5, 6, 13]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [6, 28]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [15, 18]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 9, 14, 16]}\n    ],\n    \"complexes\": [\"Ribonucleotide reductase (R1/p53R2 holoenzyme)\"],\n    \"partners\": [\"RRM1\", \"TP53\", \"CDKN1A\", \"MAP2K2\", \"ATM\", \"PYCR1\", \"PYCR2\", \"TXNRD2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}